Karyopharm announces new selinexor data in myelofibrosis and multiple myeloma to be presented at ash 2022

–  encouraging data observed in phase 1 study of selinexor in combination with ruxolitinib in treatment-naÏve myelofibrosis, including activity across three key efficacy endpoints of spleen volume reduction, symptom improvement , and hemoglobin stabilization, with a generally manageable tolerability profile and  no dose limiting toxicities – – new data on triple class refractory multiple myeloma patients continue to highlight the efficacy and tolerability of selinexor in the treatment of multiple myeloma – newton, mass. , nov. 3, 2022 /prnewswire/ -- karyopharm therapeutics inc. (nasdaq: kpti), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that two abstracts detailing new selinexor data have been selected for poster presentation at the 64th american society of hematology (ash) annual meeting and exposition taking place december 10-13, 2022.
KPTI Ratings Summary
KPTI Quant Ranking